Evaluation of the Stability of Ketoprofen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Author(s): Peacock Gina F, Sauvageot Jurgita, Addo Richard T
Issue: Jul/Aug 2014 - Volume 18, Number 4
View All Articles in Issue
Page(s): 348-350
Note: Electronic version includes errata or revisions.
Download in electronic PDF format for $75
Abstract: Previous reports indicate that pharmacists are assigning a wide variety of beyond-use dates to extemporaneously compounded medications in topical Pluronic lecithin organogel. The objective of this study was to evaluate the stability of ketoprofen in Pluronic lecithin organogel over a period of six months and to determine an appropriate beyond-use date for this formulation. A stability-indicating high-performance liquid chromatography method for ketoprofen in Pluronic lecithin organogel was validated in our laboratory. Samples of the formulation were analyzed by high-performance liquid chromatography at 0, 7, 14, 21, 28, 45, 60, 90, and 180 days. At each time point, the average concentration and average percent of initial concentration were calculated. The beyond-use date was determined as the time period that the samples were physically stable and maintained at least 90% of the initial concentration. Ketoprofen in Pluronic lecithin organogel was chemically and physically stable for six months when stored at room temperature and protected from light. Therefore, a beyond-use date of six months is appropriate for this preparation.
Related Keywords:
Gina F. Peacock, PhD, Jurgita Sauvageot, PharmD, Richard T. Addo, PhD, ketoprofen, Pluronic lecithin organogel, topical preparations, transdermal vehicle, stability, beyond-use dates, formulations
Related Categories:
EXCIPIENTS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, ALLERGY/IMMUNOLOGY/INFLAMMATION, DOSAGE FORMS/DRUG CARRIERS, STORAGE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Evaluation of the Stability of Ketoprofen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Peacock Gina F, Sauvageot Jurgita, Addo Richard T
|
Jul/Aug 2014
Pg. 348-350
|
Evaluation of the Stability of Promethazine Hydrochloride in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Peacock Gina F, Sauvageot Jurgita
|
Jul/Aug 2014
Pg. 345-347
|
Evaluation of the Stability of Fluoxetine in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Peacock Gina F, Sauvageot Jurgita
|
May/Jun 2014
Pg. 253-255
|
In Vitro Percutaneous Absorption of Ketoprofen and Testosterone: Comparison of Pluronic Lecithin Organogel vs. Pentravan Cream
Lehman Paul A, Raney Sam G
|
May/Jun 2012
Pg. 248-252
|
Preparation and In Vitro Evaluation of a Pluronic Lecithin Organogel Containing Ricinoleic Acid for Transdermal Delivery
Boddu Sai HS, Bonam Sindhu Prabha, Wei Yangjie, Alexander Kenneth
|
May/Jun 2014
Pg. 256-261
|
Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Hong Eun Ji, Sumanasekera Wasana, Le Uyen Minh
|
Jan/Feb 2022
Pg. 65-71
|
Evaluation of the Stability of Acetaminophen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-Use Date
Peacock Gina F, Sauvageot Jurgita
|
Sep/Oct 2012
Pg. 428-430
|
Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study
Glisson James K, Wood Rebecca L, Kyle Patrick B, Cleary John D
|
May/Jun 2005
Pg. 242-246
|
Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs
Frankum James, Ramsay Dale, Das Nandita G, Das Sudip K
|
Mar/Apr 2004
Pg. 101-105
|
Baclofen 5%, Capcaicin 0.075%, Ketoprofen 10%, and Tetracaine 2% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Nov/Dec 2010
Pg. 513
|
Baclofen 5%, Gabapentin 5%, Ketoprofen 10%, and Lidocaine 5% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Nov/Dec 2010
Pg. 514
|
Amitriptyline Hydrochloride 2%, Baclofen 5%, Ketamine Hydrochloride 5%, Ketoprofen 10% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Nov/Dec 2010
Pg. 512
|
Ketoprofen 10%, Ibuprofen 10%, Cyclobenzaprine Hydrochloride 2%, and Piroxicam 2% in Pluronic Lecithin Organogel Gel
Allen Loyd V Jr
|
May/Jun 2011
Pg. 245
|
Ketoprofen 10% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 319
|
Ketoprofen 10% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 52
|
Ketoprofen 10% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Mar/Apr 2019
Pg. 150
|
The History of Pluronic Lecithin Organogel: An Interview With Marty Jones, BSPharm, FACA, FIACP
Allen Loyd V Jr
|
May/Jun 2003
Pg. 180-183
|
Morphine Sulfate 50 mg/mL in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
May/Jun 2009
Pg. 244
|
Oxycodone Hydrochloride 10 mg/mL in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
May/Jun 2009
Pg. 245
|
Effect of Formulation pH on Transdermal Penetration of Antiemetics Formulated in Poloxamer Lecithin Organogel
Woodall Rachel, Arnold John J, McKay Doug, Abill C Scott
|
May/Jun 2013
Pg. 247-253
|
Return to Top |